UBS Group
BLPH

UBS Group’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

UBS Group’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,297
Closed -$2.07K – 11553
2022
Q4 		$2.07K Buy
+2,297
New +$2.35K ﹤0.01% 9740
2022
Q2 		– Sell
-2,571
Closed -$6K – 11766
2022
Q1 		$6K Buy
2,571
+351
+16% +$836 ﹤0.01% 9076
2021
Q4 		$7K Buy
2,220
+1,049
+90% +$3.48K ﹤0.01% 9231
2021
Q3 		$4K Sell
1,171
-2,190
-65% -$9.13K ﹤0.01% 8776
2021
Q2 		$16K Buy
3,361
+1,258
+60% +$5.64K ﹤0.01% 7624
2021
Q1 		$11K Buy
2,103
+450
+27% +$3.13K ﹤0.01% 7902
2020
Q4 		$11K Sell
1,653
-477
-22% -$3.9K ﹤0.01% 7463
2020
Q3 		$22K Buy
2,130
+1,044
+96% +$12.3K ﹤0.01% 6262
2020
Q2 		$14K Buy
1,086
+192
+21% +$2.69K ﹤0.01% 6815
2020
Q1 		$10K Buy
894
+60
+7% +$402 ﹤0.01% 6966
2019
Q4 		$4K Buy
+834
New +$5.3K ﹤0.01% 7718
2019
Q3 		– Sell
-733
Closed -$7K – 8483
2019
Q2 		$7K Sell
733
-553
-43% -$5.3K ﹤0.01% 7287
2019
Q1 		$13K Buy
1,286
+19
+1% +$209 ﹤0.01% 6666
2018
Q4 		$15K Buy
1,267
+189
+18% +$2.74K ﹤0.01% 7010
2018
Q3 		$17K Buy
1,078
+972
+917% +$23.1K ﹤0.01% 6904
2018
Q2 		$4K Sell
106
-305
-74% -$10.6K ﹤0.01% 7595
2018
Q1 		$13K Buy
+411
New +$13.1K ﹤0.01% 6740
2017
Q3 		– Sell
-671
Closed -$13K – 8163
2017
Q2 		$13K Buy
+671
New +$13.9K ﹤0.01% 6618
2016
Q4 		– Sell
-618
Closed -$13K – 8201
2016
Q3 		$13K Buy
618
+567
+1,112% +$13.7K ﹤0.01% 6627
2016
Q2 		$1K Sell
51
-29
-36% -$795 ﹤0.01% 7602
2016
Q1 		$3K Buy
80
+18
+29% +$667 ﹤0.01% 7242
2015
Q4 		$3K Sell
62
-363
-85% -$17.6K ﹤0.01% 7927
2015
Q3 		$33K Buy
425
+382
+888% +$29.4K ﹤0.01% 6218
2015
Q2 		$5K Sell
43
-54
-56% -$7.34K ﹤0.01% 7903
2015
Q1 		$13K Buy
+97
New +$15.1K ﹤0.01% 7452

Other funds holding BLPH

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group's BLPH Position: Q1 2023 in Review

UBS Group sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q1 2023, closing a stake of 2,297 shares — an estimated $2.07K sold.

UBS Group first reported a position in BLPH in Q1 2015 and held it in 25 quarters. The position peaked at $33K in Q3 2015. 19 funds tracked by Wall St. Rank hold BLPH as of Q1 2023.

  • UBS Group reported no remaining Bellerophon Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 2,297 Bellerophon Therapeutics, Inc. shares in Q1 2023, an estimated $2.07K.
  • UBS Group first reported a position in Bellerophon Therapeutics, Inc. in Q1 2015 and held it in 25 quarters.
  • UBS Group's Bellerophon Therapeutics, Inc. position peaked at $33K in Q3 2015.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.